Nippon Shinyaku Co., Ltd., a pharmaceutical company based in Japan, specializes in manufacturing specialty and generic drugs. With a medium risk rating score of 26.2, the company focuses on ESG principles in its research and development activities including pharmaceuticals, nutraceuticals, and genomic drug discovery. Nippon also develops health food ingredients and protein preparations. The company is open to merger and acquisition investments to expand its operations and market reach.